Background Transplantation is the main palliative treatment for patients with heart failure. Clinical signs of cardiac rejection can be very non-specific or even absent. Thus, successfull management relies on early diagnosis, ideally before the onset of clinical features of cardiac dysfunction. Although endomyocardial biopsy (EMB) is the reference diagnostic method, several non-invasive methods have been proposed to reduce the number of EMB performed during the follow-up of the transplanted patient. The aim of the present work was to study the potential relationship between rejection and serum concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP) as well as cardiac troponin T (cTnT) in posttransplantation patients.
Introduction
Transplantation constitutes a life-saving alternative for those patients su¡ering from terminal insu⁄ciency in an organ or tissue. Unfortunately, cardiac transplantation remains a palliative rather than de¢nitive therapy, providing a mean survival time of 9.6 years. 1 Rejection reaches the highest rate during the ¢rst month posttransplantation, acute failure of the graft being the main cause of death in this period. 2 Clinical signs of cardiac rejection can be very non-speci¢c or even absent. Thus, successful management relies on early diagnosis. Endomyocardial biopsy (EMB) is the reference diagnostic method which allows the strati¢cation of the rejection severity. The pathologic classi¢cation of the rejection severity has been established by the International Society of Heart and Lung Transplantation. 3 A protocol of serial EMB is usually performed on these patients with immunotherapy being applied immediately following the detection of a rejection episode.
There are three main problems associated with EMB. First, as it is an invasive method, it carries an inherent risk to the patient; second, interpretation of a humoral rejection is sometimes di⁄cult; and ¢nally, due to random sampling of the graft, EMB may give false-negative results in cases of focal rejection. 4, 5 Several non-invasive methods have been proposed in order to reduce the number of EMB performed during the follow-up of the transplanted patient. However, EMB remains the gold standard method. 4 Among all of the potential biochemical markers, cardiac troponin T (cTnT) has been the most studied test. Structural integrity of the cellular membrane is lost when a necrotic process takes place in the myocardial cells. It is well established that cTnT plasma concentrations are increased during the ¢rst month posttransplantation in response to surgery-related trauma. 6, 7 However, contradictory results have been reported with regard to a potential relationship between rejection and plasma concentration of cTnT as a marker of myocardial necrosis. Higher concentrations of cTnT have been found in blood taken from a central line in patients diagnosed with cardiac rejection, 8 providing useful information complementary to the EMB. Chance et al. 7 even found a correlation between a cTnT value higher than 0.1 mg/L and a rejection grade X3 in nearly all cases. However, other groups did not ¢nd any signi¢cant relationship between cTnT and the rejection grade of a cardiac transplantation. 9, 10 Therefore, further investigations are still necessary in order to elucidate the potential utility of cTnT as a marker of the rejection grade in speci¢c groups of transplanted patients.
Plasma concentrations of natriuretic peptides also increase in response to the myocardial stress produced by cardiac insu⁄ciency. In the ¢rst few days after transplantation, high plasma concentrations of natriuretic peptides are found, even after left ventricular function is restored. 11, 12 Atrial natriuretic peptide (ANP) plasma concentrations signi¢cantly decrease in the two months post-transplantation, and no further alterations are observed during the ¢rst year. 12 However, brain natriuretic peptide (BNP) concentrations decrease throughout the ¢rst year after transplantation; they do not reach normal values, although they plateau after the fourth or the ¢fth month. 13 The utility of BNP in the follow up of cardiac transplantation has not yet been totally elucidated. Several studies reported the use of BNP concentrations as a non-invasive method to predict the presence of rejection, but results are controversial. O'Neill et al. 14 conclude that BNP is not a valid marker for diagnosing grade 42 rejection in a study performed during the ¢rst two months after transplantation. Other authors 15 found slightly higher values of BNP in patients with treatable rejection, depending on the rejection grade and time post-transplantation, but they did not manage to establish a cut-o¡ point with discriminatory capacity. It seems that haemodynamic changes observed during a rejection episode lead to an increase in blood BNP concentrations. 13, 16 Therefore, similar increases either in plasma or serum N-terminal pro-brain natriuretic peptide (NT-proBNP) concentrations should be expected, although this parameter has not been widely studied.
The aim of the present work is the study of a potential relationship between rejection and serum concentrations of NT-proBNP and cTnT in post-transplantation patients.
Materials and methods
Twenty-three consecutive orthotopic heart transplantation recipients with a mean age of 51 years (range 22--66) were prospectively recruited from the cardiac transplantation programme at the Hospital Universitario Central de Asturias between August 2002 and January 2004. Informed consent was received from each subject, but formal ethics committee approval was not sought. One heart--kidney transplantation patient was excluded from the study, as were two other patients who died before the third biopsy.
In the remaining 20 patients (4 women and 16 men), heart transplantation had been indicated because of the following diagnosis: advanced ischaemic heart disease (n ¼10), idiopathic dilated cardiomyopathy (n ¼ 3), hypertrophic cardiomyopathy (n ¼ 3), restrictive cardiomyopathy (n ¼1), acute myocardial infarction with severe pulmonary oedema (n ¼1), coronary graft disease (n ¼1) and post-cardiac-surgery heart failure (n ¼1). Follow-up ranged from 9 to 13 months after transplantation (mean 1171.5 months).
After transplantation, serial EMBs were performed on all patients as part of the follow-up protocol of the Cardiac Transplantation Unit: at 15 days postoperative, every month during the next six months and at 9 and 12 months. When a rejection episode occurred, biopsies were repeated more often. After the ¢rst year, EMB was performed only when it was clinically indicated. The histological diagnosis of graft rejection was de¢ned according to the classi¢cation of the International Society of Heart and Lung Transplantation (ISHLT). 3 Only rejection episodes graded 3A or higher were treated with anti-rejection therapy.
Peripheral venous blood was collected into clotactivating gel tubes just before performing each EMB. After centrifugation at 2000 g for 8 min, serum was separated and stored at À801C until analysis.
NT-proBNP and cTnT serum concentrations were analysed on an Elecsys 2010 (Roche Diagnostics, Mannhein, Germany) by two-site sandwich electrochemiluminescense immunoassay. Calibrations were performed once per reagent lot for each assay, and two concentrations of quality control (PreciControl Cardiac Ann Clin Biochem 2007; 44: 182-188 1 and 2, PreciControl TNT, 1 and 2, respectively) were analysed twice per run. Previously published reference ranges were used. 17, 18 Medical records of each patient were studied to identify patients with renal insu⁄ciency (RI) (serum creatinine X176.8 mmol/L), and to identify the right ventricle systolic pressure (RVP) measurement at the time of EMB.
As non-Gaussian distributions of the results were obtained, non-parametric methods of statistical analysis were applied (Mann--Whitney U-test, Spearman correlation), with a signi¢cant P value o0.05. The SPSS statistical package (v11.0 for Windows) was used.
Results
A total of 171 endomyocardial biopsies were performed in the 20 patients involved in the two years study, with a mean of nine EMBs per patient (range:7--10).
NT-proBNP concentrations decreased throughout the ¢rst year post-transplantation (Spearman correlation coe⁄cient --0.48; Po0.0001), showing a plateau after the ¢fth month without reaching normal values. cTnT concentrations decrease during the ¢rst two months after transplantation (Spearman correlation coe⁄cient À0.72, Po0.0001), but no signi¢cant relationship between cTnT concentration and posttransplantation time was found beyond the second month.
Comparison between biochemical parameters and EMB diagnosis was performed after the ¢rst postoperative month in order to avoid the confounding e¡ect of ischemic tissue injury.
Although a statistically signi¢cant correlation was observed between RVP and NT-proBNP concentrations, the linear association between both parameters was weak (Spearman correlation coe⁄cient 0.22; Po0.01). This correlation was not statistically signi¢cant for cTnT.
Serum NT-proBNP and cTnT concentrations were signi¢cantly higher in patients with renal insu⁄ciency than in those with normal renal function (Po0.01, Mann--Whitney U-test). Normal values of cTnT were not reached in the ¢rst three months after transplantation. Afterwards, serum cTnT progressively decreased to undetectable concentrations by 3-5 months posttransplantation only in those patients with normal renal function.
A broad range of NT-proBNP concentrations was found in patients with rejection o3A (median 127.7 pmol/L, interquartile range 62.9--254.2 pmol/L) and in patients with rejection X3A (median 183.6 pmol/L, interquartile range 73.8--405.2 pmol/L). So interpretation of the results was mainly based on the change observed in relation to the value obtained at the previous EMB time. Since NT-proBNP concentra-tions are in£uenced by renal status, it is important to point out that no signi¢cant di¡erences were found between creatinine concentrations in both no rejection and X3A rejection groups (Mann--Whitney U-test).
Eight out of the 20 studied patients su¡ered an episode of signi¢cant rejection (grade 3A or higher), which required treatment, and one of them went through several consecutive positive EMB results. In eight out of the 12 patients without a signi¢cant rejection episode, NT-proBNP concentrations decreased throughout the ¢rst year post-transplantation (Figure1a).The remaining four patients without a rejection diagnosis showed increases in NT-proBNP concentrations associated to clinical causes di¡erent from rejection, such as £utter, infection, necrosis and in£ammation ( Figure 1b ). Signi¢cantly higher increases of NT-proBNP concentrations were observed in those patients with a rejection grade X3A than those observed in patients with rejection grades o3A on EMB (Po0.01, Mann--Whitney U-test). The outliers and extreme values observed in the non-rejection group in Figure 2 correspond to patients that showed signi¢cant increases in NT-proBNP concentrations associated with clinical causes other than rejection. No signi¢cantly di¡erent cTnT concentrations were observed in both groups of patients.
Seven out of the eight patients with treatable rejection showed an increase in NT-proBNP concentrations at the time or even some weeks before the rejection diagnosis by EBM (Figure 3 
Discussion
Transplantation is the main palliative treatment for patients with heart failure. During the ¢rst month after transplantation, high concentrations of serum cTnT have been reported elsewhere in the body 7 which could be explained by cardiac ischaemia and surgical trauma produced by having aggresive surgery. On the other hand, as natriuretic peptide concentrations are elevated in heart failure, the transplanted patients also have high concentrations before transplantation. 19, 20 After transplantation, these peptides are produced by the new heart. In previous studies, elevation of the post-transplantation atrial natriuretic peptide (ANP) concentration was described, followed by a decrease during the ¢rst two months postoperatively but no further change up to 12 months. 12 Furthermore, brain natriuretic peptide (BNP) concentrations showed a tendency to decrease during the ¢rst year, but do not reach normal concentrations. 12, 21 However, Herva Ł s et al. described that NT-proBNP had the tendency to reach a plateau after the fourth or ¢fth month. 13 ANP elevation in post-transplanted patients is the normal physiological response to the hypertension and increased retention of water and salt. 11 In these patients, activation of the vasopressin and renin--angiotensin--aldosterone system takes place due to the cardiac denervation and the treatment with cyclosporine A. Cardiac natriuretic peptides spontaneously antagonize this e¡ect. 11 In the present work, raised NT-proBNP and cTnTconcentrations were observed in all of the patients just after transplantation. Comparison between biochemical parameters and EMB diagnosis was therefore performed after the ¢rst postoperative month in order to avoid the confounding e¡ect of ischaemic tissue injury.
With regard to cTnT, patients without renal insu⁄ciency had raised concentrations of cTnT even at the third to ¢fth postoperative months, but afterwards cTnT concentration became undetectable. High concentrations of cTnT were found in patients with RI throughout the ¢rst year after transplantation. This fact agrees with the previously described observation of increased cTnT concentrated in quite a high percentage of non-transplanted RI patients. 22 In the present work, no relation was observed between cTnT percentage of variation and graft rejection.
More interesting results were found regarding to NT-proBNP, where concentrations decreased throughout the ¢rst year reaching concentrations higher than the reference values adjusted by sex and gender. 17 The mean serum values of NT-proBNP in patients with no rejection or low rejection grade at 6, 9 and 12 months post-transplantation were 104.8, 95.9 and 96.6 pmol/L, respectively. This means that, in the absence of complications, NT-proBNP concentrations remain more or less constant after sixth months (Figure 1 ). These results are in good agreement with those published by Herva¤ s et al. 13 in relation to BNP, which concentrations are also nearly constant from the ¢fth month after transplantation. They also described that BNP concentrations do not show relationship to creatinine concentration in heart transplantation recipients. However, we found higher concentrations of NT-proBNP in patients su¡ering from RI compared with those without. For this reason, the range of NT-proBNP concentrations in patients without rejection one year posttransplantation was very broad, from 21.6 to 221.6 pmol/L. On that score, NT-proBNP has been proposed as a neurohumoral marker of integrated cardio-renal function by other authors, 23 and Ambrosi et al. 24 found correlation between creatinine and NT-proBNP serum concentrations in heart transplantation recipients.
In four patients without a treatable rejection, increases in NT-proBNP concentrations were observed leading to percentages of change similar to those observed in the 3A rejection group (Figure 2 ). All of these increases were associated with clinical causes other than rejection, such as £utter, infection, necrosis and in£ammation. 25--27 The mechanism of cardiac natriuretic peptide release is through increased wall stress as a result of volume or pressure loading of the ventricle. Therefore, elevation of NT-proBNP would be expected in those patients a¡ected by haemodynamic alterations. In fact, £utter is a known clinical cause of increased serum NT-proBNP concentrations. 19, 28 As rejection and the quilty e¡ect are sometimes di⁄cult to di¡erentiate by EMB, it would be interesting to con-¢rm in a larger study whether the appearance of increasing concentrations of NT-proBNP in response to clinical conditions other than rejection can provide useful complementary information to EBM in the follow-up of transplanted patient.
On the other hand, in the present work, seven out of eight patients who su¡ered X3A grade rejection were correctly diagnosed based on an increase in NT-proBNP serum concentrations at the time of the diagnosis made by EBM compared with the previous concentrations obtained during follow up. Moreover, the increase in serum NT-proBNP was observed before the diagnosis by EBM in all of these seven cases. In Figure 3 it can be seen that due to the wide variation in NT-proBNP between one patient and another, the percentage change in NT-proBNP concentrations at the time of the diagnosis is a more useful follow-up parameter. This is a very encouraging result because it seems that early diagnosis might be possible by serial measurement of NT-proBNP concentrations, in between the monthly EBM. In fact, we observed one case (Figure 3 , patient G) with a peak NT-proBNP concentration 15 days before detecting features of regression of a previous rejection by the EBM performed at the fourth month. However, the EBM result at month 3 had been a grade 1A, and a grade 3A rejection was identi¢ed at ¢fth month. Therefore, the rise in NT-proBNP concentrations observed at 3.5 month would have been useful for an early diagnosis of rejection. It was also noticed that this patient had several consecutive grade 3A rejections by EMB after the ¢fth month post-transplantation. The cardiology interpretation of this case was the presence of a single rejection event that did not respond to the corticosteroid treatement. Since a considerable NT-proBNP elevation was only observed at the time of ¢rst diagnosis, it remains unclear whether the utility of NT-proBNP would be limited in patients receiving the high-dose steroid treatment, which is used after a rejection event. It will be necessary to study more patients with poor response to rejection therapy, or multiple rejection episodes, in order to clarify this point. With regard to cTnT, there is no relation between serum concentrations and rejection.
Only one patient with a grade 3A rejection, diagnosed by EMB at month 12 of the follow-up (Figure 3 , patient H), did not show any signi¢cant increase in NT-proBNP concentrations but, interestingly, he did not have any clinical features of rejection. In order to know whether this is false-positive diagnosis of rejection by EMB, a higher number of patients with similar features will need to be studied.
On the other hand, elevations of NT-proBNP concentrations were observed during the follow up of two other patients that had been previously diagnosed with a rejection (Figure 3 , patients B and C). Similar to the previously described elevations found in four of the 12 patients without rejection, the observed increases in patient B (92% at month 5) and patient C (170% at month 12) were associated with clinical signs of haemodynamic changes.
Receiver operator curve (ROC) analysis of our 20 patients data showed that the percentage of change in NT-proBNP concentrations at the ¢rst rejection diagnosis has a diagnostic e⁄ciency of 76.2% (Po0.005). If a cut-o¡ point of 39% was established, 87.6% sensitivity would be obtained with 70% speci¢city. Recently, Ogawa et al. 10 described higher NT-proBNP plasma concentrations, measured by radioimmunoassay, in cases of grade 3 cardiac rejection with no relationship to posttransplantation time. These results are in agreement with our present ¢ndings.
Very high concentrations of NT-proBNP were found in the two patients who died during the two-month period after transplantation (2033.4 and 6794.4 pmol/L, respectively, data not shown). These data suggest that measuring NT-proBNP concentrations during the ¢rst 2--3 months after transplantation could be considered for further studies as a potential marker of prognostic value.
In this work, promising results were found about the potential utility of NT-proBNP as a non-invasive marker of transplantation rejection. High increases in NT-proBNP concentrations were observed if a signi¢cant ¢rst rejection event took place in the ¢rst year of follow-up. In addition, an earlier diagnosis could be obtained by a close examination of those patients who have signi¢cant rises in NT-proBNP concentrations during the follow-up. However, ¢nding a cut-o¡ for change in NT-proBNP concentrations, which could discriminate those patients at low risk of having a rejection, remains a very interesting challenge for further investigations.
